As an inhibitor of norepinephrine release, dexmedetomidine provides no improvement on stroke-associated pneumonia in mice
Background: Dexmedetomidine (DEX) is commonly employed as a sedative agent to attenuate sympathetic tone and reduce norepinephrine (NE) levels. In the context of stroke-associated pneumonia (SAP), which is believed to arise from heightened sympathetic nervous system activity and elevated NE release,...
Main Authors: | Miaomiao Zhou, Qiong Luo, Younian Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1203646/full |
Similar Items
-
Intraoperative dexmedetomidine attenuates norepinephrine levels in patients undergoing transsphenoidal surgery: a randomized, placebo-controlled trial
by: RyungA Kang, et al.
Published: (2020-05-01) -
Association between malnutrition and stroke-associated pneumonia in patients with ischemic stroke
by: Dongze Li, et al.
Published: (2023-08-01) -
Comparison of the Predictive Value of Inflammatory Biomarkers for the Risk of Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke
by: Li J, et al.
Published: (2023-09-01) -
The Relationship Between Serum YKL-40 Levels on Admission and Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke
by: Shi G, et al.
Published: (2021-09-01) -
Early and long-term outcomes of ischemic stroke in patients with stroke-associated pneumonia
by: Liana V. Santikova, et al.
Published: (2021-12-01)